) reached a 52-week high of $111.32 during the course of the
trading session on Nov 19, 2013. The closing price of $110.00 of
the company reflects a robust year-to-date return of 101.5%.
ACTELION LTD (ALIOF): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.
The specialty biopharmaceutical Zacks #1 Rank (Strong Buy)
company has a market cap of $6.3 billion. Average volume of
shares traded during the trading session stood at 762,911.
The Growth Story
Shares of the company started escalating following the release of
its impressive third quarter 2013 results.
Jazz Pharma reported third quarter 2013 results on Nov 5.
Adjusted earnings of $1.66 per share were well above the Zacks
Consensus Estimate of $1.52 and the year-ago adjusted earnings of
$1.22 per share. Including stock-based compensation expense and
depreciation, earnings were $1.61 per share.
Performance of the company's key growth drivers, Xyrem
(narcolepsy) and Erwinaze (oncology), were promising in the third
quarter of 2013. While Xyrem sales increased 50% to $153.7
million, Erwinaze generated revenues of $44.1 million, up 39%
year over year.
Both products are witnessing strong demand, which is expected to
boost revenues. Xyrem net sales in 2013 are expected in the range
of $565-$570 million as compared to $378.7 million in 2012. In
2013 Erwinaze net sales are expected in the range of $173-$178
million compared with $72.1 million in the prior year.
Based on its progress, the company raised the low end of its
earnings per share projection to $6.30 to $6.40 per share
(previous guidance: $6.20 to $6.40). Jazz Pharma tweaked its
revenue guidance to $867-$877 million from $860-$880 million
On a price-to-sales basis, Jazz Pharma is trading at 8.2x,
reflecting a huge premium of 134.3% compared with the peer group
average of 3.5x. On a price-to-book basis, the stock is also
trading at a premium to the peer group average. Given the
company's strong fundamentals, the premium valuation is
The Zacks Consensus Estimate for 2013 increased 10 cents to $5.77
per share over the last 30 days on the back of positive estimate
revisions. For 2014, estimates were revised higher over the same
time frame, lifting the Zacks Consensus Estimate by 43 cents to
$7.78 per share.
Lannett Company, Inc.
) too carry Zacks #1 Rank.